WallStSmart

BioLineRx Ltd (BLRX)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BioLineRx Ltd generates 89% more annual revenue ($1.40M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. BLRX earns a higher WallStSmart Score of 43/100 (D).

BLRX

Hold

43

out of 100

Grade: D

Growth: 6.3Profit: 2.5Value: 6.7Quality: 5.0
Piotroski: 5/9Altman Z: -12.62

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BLRX3 strengths · Avg: 10.0/10
PEG RatioValuation
0.2010/10

Growing faster than its price suggests

Price/BookValuation
0.9x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
87.1%10/10

Revenue surging 87.1% year-over-year

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

BLRX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$14.76M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-53.3%2/10

ROE of -53.3% — below average capital efficiency

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BLRX

The strongest argument for BLRX centers on PEG Ratio, Price/Book, Revenue Growth. Revenue growth of 87.1% demonstrates continued momentum. PEG of 0.20 suggests the stock is reasonably priced for its growth.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : BLRX

The primary concerns for BLRX are EPS Growth, Market Cap, Profit Margin.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

BLRX profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

BLRX is growing revenue faster at 87.1% — sustainability is the question.

BLRX generates stronger free cash flow (-2M), providing more financial flexibility.

Bottom Line

BLRX scores higher overall (43/100 vs 24/100) and 87.1% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BioLineRx Ltd

HEALTHCARE · BIOTECHNOLOGY · USA

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company is headquartered in Hevel Modi'in, Israel.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?